Obesity-Focused Biotech Kailera Joins IPO Queue in US

Obesity drugmaker Kailera plans an IPO

The company, led by Ron Renaud, raised $1 billion in venture funding to develop a competitor to Wegovy and Zepbound that’s now in late-stage testing.

Obesity-focused biotech Kailera joins IPO queue in US

Kailera Therapeutics has filed for an IPO, ​hoping to whet investor appetites with its pipeline of drug candidates for weight loss

Kailera plans IPO to raise money for its China-licensed obesity pipeline

One of biotech's best-funded startups plans to go public, as it seeks to take its obesity portfolio into a market crowded by Eli Lilly, Novo Nordisk and other next-generation obesity contenders. Kailera Therapeutics